With all the opioid lawsuits against drug manufactors NKTR stands as a clear choice for massive future gains. Why? NKTR has made a non-addictive opioid pending FDA Approval. Everyday 130 people die from overdosing on some form of opioid which is why creating a safe, non-addictive opioid is a huge feat.
This stock is at an incredible value, and the risk v reward is highly favored toward reward. If this company gets FDA approval for this drug it will skyrocket back to previous highs of 100+. I'm in for the long term, but there are plenty of short term opportunites here. Don't miss out on this incredible opportunity!
FDA approval date is unknown and was pushed back due to on-going lawsuits regarding opioids in general.
NKTR-181 (loxicodegol) is a novel mu-opioid agonist molecule designed to have a slow rate of entry into the brain thus reducing abuse potential and CNS-mediated side effects. NKTR-181 is in development for the treatment of chronic low back pain in adult patients new to opioid therapy.
Do your own research.
This stock is at an incredible value, and the risk v reward is highly favored toward reward. If this company gets FDA approval for this drug it will skyrocket back to previous highs of 100+. I'm in for the long term, but there are plenty of short term opportunites here. Don't miss out on this incredible opportunity!
FDA approval date is unknown and was pushed back due to on-going lawsuits regarding opioids in general.
NKTR-181 (loxicodegol) is a novel mu-opioid agonist molecule designed to have a slow rate of entry into the brain thus reducing abuse potential and CNS-mediated side effects. NKTR-181 is in development for the treatment of chronic low back pain in adult patients new to opioid therapy.
Do your own research.
Trade attivo:
Bought more yesterday at $17 level. Can't see it dropping below that major support but we will see. Remaining Long
I'm buying more and more shares of this company, ppl are crazy.